Boehringer Ingelheim and the Mary Tyler Moore Vision Initiative (MTM Vision) today jointly announce the start of a long-term ...

Boehringer Ingelheim and MTM Vision join forces to combat vision loss from diabetes: Ingelheim, Germany Wednesday, November 13, 2024, 10:00 Hrs [IST] Boehringer Ingelheim and the ...

In a small Phase IIa trial, Insilico’s generative AI-designed idiopathic pulmonary fibrosis drug improved lung function and ...

Ingelheim, Germany and Ann Arbor, MI, USA, November 12, 2024 – Boehringer Ingelheim and the Mary Tyler Moore Vision Initiative (MTM Vision) today jointly announce the start of a long-term ...

SAN ANTONIO -- Research presented at the ObesityWeek annual meeting included studies on rationing of prescription medications ...

SAN ANTONIO — Oral semaglutide 25 mg appears to be just as effective in promoting weight loss and other beneficial outcomes ...

People with chronic kidney disease, Type 2 diabetes or both were predicted to have elevated cardiovascular disease (CVD) risk 8 to 28 years sooner than someone without those conditions, according to a ...

Recent developments driving growth in this area make the advanced, AI-supported digitization of pharma pipelines inevitable.

Junior Professor Johannes Walker, University of Göttingen, has been awarded an Exploration Grant from the Boehringer Ingelheim Foundation. Walker teaches and carries out research at the Institute for ...

SAN ANTONIO -- Patients with overweight or obesity lost an average one-fifth of their body weight with the highest dose of ...